1. Home
  2. ZH vs NGNE Comparison

ZH vs NGNE Comparison

Compare ZH & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhihu Inc. (every two of each representing one ordinary share)

ZH

Zhihu Inc. (every two of each representing one ordinary share)

HOLD

Current Price

$3.54

Market Cap

293.3M

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$17.43

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZH
NGNE
Founded
2011
2003
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.3M
327.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ZH
NGNE
Price
$3.54
$17.43
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$40.14
AVG Volume (30 Days)
311.4K
111.0K
Earning Date
03-25-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.17
N/A
Revenue
$416,437,241.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.97
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.23
$6.88
52 Week High
$6.32
$37.27

Technical Indicators

Market Signals
Indicator
ZH
NGNE
Relative Strength Index (RSI) 44.75 45.98
Support Level $3.41 $16.20
Resistance Level $3.76 $17.95
Average True Range (ATR) 0.17 1.36
MACD -0.02 0.02
Stochastic Oscillator 25.49 34.81

Price Performance

Historical Comparison
ZH
NGNE

About ZH Zhihu Inc. (every two of each representing one ordinary share)

Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: